Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003472526 | SCV004204199 | likely pathogenic | Aplastic anemia | 2023-09-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003626869 | SCV004405958 | pathogenic | Familial hemophagocytic lymphohistiocytosis 2 | 2024-10-14 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 2 of the PRF1 gene. While this variant is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PRF1-related conditions. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts a region of the PRF1 protein in which other variant(s) (p.Gln446Pro) have been determined to be pathogenic (PMID: 25326637, 26450956). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |